Medication for prevention and treatment of mycotoxicoses of small ruminants

FIELD: agriculture.

SUBSTANCE: medication comprises humic acids, fine silica, selenium taken of small-size condition and zero valency, fat-soluble vitamin E, and distilled water. The components are taken in a specific ratio.

EFFECT: use of the invention enables to prevent and treat gastrointestinal diseases of animals, including those related to mycotoxins.

2 tbl, 4 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves a combined administration of the preparations Enterosgel, Kudesan and Pantogam. Enterosgel is administered orally in the form of gel 30 minutes before meals in a dose of 1 teaspoon two times a day for 7 days. Kudesan is also administered orally during meals before noon in an age dose of: 10-16 drops (15-24 mg) in the children aged 5 through 7 years old, 16-20 drops (24-30 mg) in the children aged 8 through 10 years old, pre-dissolved in a small amount of boiled water or other beverage of room temperature, once a day in the course of 30 days. Pantogam is administered orally 15-20 minutes after meals in an age dose of: 500 mg 2 times a day in the children aged 5 through 7 years old, 500 mg 3 times a day in the children aged 8 through 10 years old in the course of 30 days.

EFFECT: complex administration regiment provides the effective correction of cognitive disorders in the given group of children by a synergetic detoxification, antioxidant and neuroprotective action of its components.

3 cl, 4 tbl

FIELD: chemistry.

SUBSTANCE: application of 5% water solution of sodium and potassium salts of humic acids, obtained from leonardite brown coal, in dose 10.0 mg/kg as membrane-protective preparation.

EFFECT: application of composition described above makes it possible to extend arsenal of membrane-protective preparations from low-toxic, cheap, available natural raw material.

2 dwg, 2 ex

FIELD: pharmacology.

SUBSTANCE: agent possessing detoxification activity, containing succinic acid, 10% ethanol extract of propolis, polyethylene glycol 400, polyethylene glycol 1500, polyethylene glycol 4000, Cremophor CO-40, Tween-80 and purified water in certain proportions.

EFFECT: agent possesses the detoxification action, the uniform release of the active substances and the pronounced prolonged action.

2 cl, 4 dwg, 4 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to radiation and experimental biology, biotechnology and medicine, namely to means of radiological protection and to stimulators of colony formation of stem cells. Invention can be used in research and clinical practice for protection of living organisms in case of exposure to ionising radiation, in emergency and military medicine, in case of emergency situations as means for protection against radiation injury. Claimed is application of preparation gamma-plant as radioprotector with colony-stimulating properties for increasing survival and improving state of organisms, subjected to irradiation. Gamma-plant is non-toxic polysaccharide of vegetable origin, registered by Ministry of Health of the Russian Federation and allowed for medical application; Gamma-plant is included into Russian Pharmacopoeia in section FG-9 "non-narcotic analgesics".

EFFECT: invention makes it possible to increase efficiency of colony formation of stem cells in spleen 2,0-2,3 times, increases survival of experimental animals to 95% with coefficient of dose reduction factor DRF, equal 2-2,2.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: medicine.

SUBSTANCE: first, Fraxiparine is inhaled for 5-10 minutes. A dialysis solution for peritoneal dialysis containing extranyl is administered into the abdominal cavity 1-1.5 hours later through a catheter. The solution additionally contains: albumin in the concentration of 35-40 g/l, heparin in the concentration of 500-750 Unit/l and papaverine in the concentration of 50-100 mg/l. Every 6-8 hours after the beginning of exposure of the dialysis solution in the abdominal cavity, the Fraxiparine inhalations are repeated. The time of a single exposure of the dialysis solution in the abdominal cavity makes 12-18 hours.

EFFECT: method provides effective body detoxification in the given category of patients by providing a high toxin clearance owing to a continuous high osmotic concentration of the solution and the dilatation of pre-capillary peritoneal arterioles, prevented inspissation of the albumin solution to the colloidal state and its inactivation that reduces a rate of the dialysis solution exchanges.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an immunomodulatory composition for injection into a mammal. The immunomodulatory composition for injection into a mammal containing a hydrolysate prepared by acid and/or enzymatic hydrolysis of one or more bioresources specified in a group consisting of bivalve molluscs, annelids, leeches, and water taken in certain proportions. A method for preparing the immunomodulatory composition for injection into a mammal. A method of treating a pathological condition in a mammal in need thereof involving the injections of the immunomodulatory composition into the above mammal. Using the composition for normalising metabolism into the mammal in need thereof.

EFFECT: composition enables extending the range of products with immunomodulatory activity for injections.

19 cl, 7 tbl, 7 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of calves with Simuliidotoxicosis is that 40% solution of urotropine is administered intravenously to calves at a dose of 1.5 ml per 10 kg of animal body weight.

EFFECT: improvement of efficiency of the method.

FIELD: medicine.

SUBSTANCE: group of inventions relates to veterinary and medicine, in particular to obtaining and application of biopreparations for immunotherapy of ecopathologies. The group of inventions includes obtaining a protein antigen from a mixture of anatoxins from three enteropathogenic virulent strains of a pathogen of escherichiosis of calves E.coli No. 378, 379, 380 by their growing on Hottinger medium with further addition of 0.4-0.5% formalin, following thermostating for 10-12 days and cooling the mixture of anatoxins with a sterile solution of aluminium hydroxide, after that obtaining radioantigen from E.coli "PL-6" by growing cultures on a meat infusion agar with further washing away a biomass by a physiological solution and irradiation of the obtained suspension with a concentration of 1.2·1010 m.c./cm3 on a gamma-installation in a dose of 140-150 Gr with following thermostating and extraction of radiotoxin with 70% acidified with 0.05% hydrochloric acid to pH 5.5 ethanol, following evaporation of the exractant to the initial volume, after that, obtaining protein-cadmium radioantigen first by preliminary dechlorination of cadmium chloride, obtaining cadmium hydroxide, addition into the obtained 2.7% solution of the antigen of 0.77% solution of cadmium hydroxide in a ratio of 1:1 with following thermostating at a temperature of 37°C for 30 minutes, evaporation and dissolution of the residue to 12.8% concentration, further obtaining protein-cadmium radioantigen by an addition of 1.2% solution of a mixture of three anatoxins of E.coli and 12.8% solution of cadmium radioantigen in a ratio of 1:9, conjugation of components at room temperature for 8-10 hours, standardisation by a dry substance to 10% concentration and pouring into vials, and storage at a temperature of 4-6°C. The group of inventions also relates to a method of treating radiation, chemical and/or bacteriological damage to an organism by introduction of 10% solution of complex protein-cadmium radioantigen.

EFFECT: application of the group of inventions is effective in treatment of radiation, chemical and/or biological damage.

4 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and particularly to preparations for a therapy of oncological diseases, treatment of allergy, prevention and health improvement. The invention represents a method for preparing fraction 4 (ADP-f4) and fraction (ADP-f5) adaptogenic Dorogov's preparations, characterised by the fact that a primary product is a fraction 2 antiseptic Dorogov's stimulator (ADP-f2) to be thermally treated.

EFFECT: implementing the given invention provides the more effective prevention and eliciting anti-stress reactions for the purpose of improving the functional state of organism and increasing a resistance in an activation therapy.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to method of obtaining encapsulated particles of metal salts. Method of obtaining particles of metal salts encapsulated in liposoluble polymer envelope consists in the fact that metal salt, selected from the group: iron sulphate, zinc sulphate, potassium iodide or calcium chloride, is dissolved in water, obtained mixture is dispersed in sodium carboxymethylcellulose in butanol in presence of E472c and mixed, with further addition of ethanol to obtained mixture, obtained suspension is filtered and dried at room temperature, under specified conditions.

EFFECT: method makes it possible to simplify and accelerate process of obtaining microcapsules.

4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to nanotechnology, particularly a method of producing aspirin nanocapsules in a carrageenan envelope. The disclosed method includes preparing an aspirin suspension in benzene; dispersing the obtained mixture into a carrageenan suspension in butanol in the presence of an E472c preparation while mixing at 1000 rps; adding tetrachloromethane; filtering the obtained nanocapsule suspension and drying at room temperature.

EFFECT: method provides a simpler and faster process of producing nanocapsules and increases mass output.

1 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of bioencapsulation and represents method of obtaining microcapsules by method of precipitation with non-solvent, which consists in the fact that water-soluble medication of cephalosporin group, applied as core of microcapsules, and E472c as surface-active substance, are added to water solution of human leukocyte interferon in α- or β- form, applied as envelope of microcapsules, mixture is mixed, after dissolution of components carbinol is added as first precipitator, with the following addition of acetone as second precipitator, with ratio of carbinol to acetone constituting 1:5, obtained suspension of microcapsules is filtered, washed and dried at 25°C.

EFFECT: invention ensures simplification and acceleration of the process of obtaining microcapsules and reduction of loss (increase of output by weight).

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a substance-delivering carrier for the substance delivery to a bone marrow cell producing an extracellular matrix containing retinoid as a delivering agent, wherein the substance is a therapeutic agent, which inhibits the beginning, progression and/or recurrence of myelofibrosis.

EFFECT: invention provides the effective inhibition of the beginning, progression and recurrence of myelofibrosis.

10 cl, 14 dwg, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to using dermatan sulphate recovered from sulodexide for treating diseases involving metalloproteinase MMP-9: varicose veins and vascular malformations accompanied by a risk of thrombosis.

EFFECT: reducing and/or inhibiting individual's blood serum and saphena segments MMP-9 has been shown.

4 cl, 3 dwg, 13 tbl

FIELD: medicine.

SUBSTANCE: method involves administering Aevit, Unidox as a background therapy of degree I and II, and Isotretinoin and Cynovit gel as a background therapy of degree III and IV. Besides, Magnerot® 3.0 g is taken once a day (1.0 g three times a day) throughout the all background therapy.

EFFECT: invention enables providing higher clinical effectiveness in the patients with acne and connective tissue dysplasia.

1 tbl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and describes a method for producing glucosamine sulphate nanocapsules by non-solvent addition, wherein glucosamine sulphate is added in small amounts to a carrageenan suspension used as a nanocapsule shell in butanol, containing E472c preparation 0.01 g as a surfactant; the produced mixture is agitated and added with the non-solvent hexane 6 ml, filtered, washed in hexane and dried.

EFFECT: invention provides simplifying and accelerating the process of nanoencapsulation in carrageenan and higher weight yield.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to microencapsulation, in particular, to microencapsulation of antioxidants. Carrageenan was used for the capsule shells, an antioxidant was selected from the group of: vitamins A, C, E, Q10, eleuterococcus, green tea extract, ginseng extract; wherein an antioxidant product portion was dissolved in dimethylsulfoxide, and the mixture was dispersed in a solution of carrageenan in ethanol in the presence of the preparation E472c under stirring at the rate of 1300 rev/s, the antioxidant/carrageenan weight ratio was 1:3, after which a mixture of benzene and water taken in volume ratio of 2:1 was added to the above mix, the resulted suspension was filtered and dried at a room temperature.

EFFECT: simplified and fast process of antioxidant product microencapsulation in carrageenan.

1 ex

FIELD: nanotechnology.

SUBSTANCE: suspension of aspirin in benzene is produced. The resulting mixture is dispersed into suspension of sodium alginate in butanol in the presence of the preparation E472s when stirring at 1000 rpm/sec. Then chloroform is poured, the resulting suspension of nanocapsules is filtered and dried at room temperature.

EFFECT: simplification and acceleration of the process of production of the nanocapsules, and increase in the yield by weight.

1 dwg, 4 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of obtaining substations based on oxidated dextran and isonicotinic acid hydrazide, which includes obtaining dextran water solution, dextran oxidation with potassium permanganate in acidic medium at heating, removal of admixtures from solution by filtration, purification of oxidated dextran water solution from manganese ions by passing at rate 100-600 ml/min through cation exchange resin, represented by cationite based on styrene copolymer with static volume capacity 1.9 g-eq/cm3, addition of powder of isonicotinic acid hydrazide and distilled water or water solution of isonicotinic acid hydrazide.

EFFECT: simplification of process of obtaining substance based on oxidated dextran and isonicotinic acid hydrazide for pharmaceutical application due to creation of conditions for minimisation of stages and used reagents with elimination of application of dangerous reagents and simultaneous obtaining target product, free of manganese ions.

2 ex

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

Up!